Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcin Kortylewski

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
Blood|June 3, 2021
Revisiting TLR9 as a target for CLL therapyMarcin Kortylewski
Cancer Immunology, Immunotherapy : CII|February 20, 2017
Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunitiesMarcin Kortylewski, Dayson Moreira
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 3, 2014
How to train your dragon: targeted delivery of microRNA to cancer cells in vivoMarcin Kortylewski, Sergey Nechaev
Methods in Molecular Biology (Clifton, N.J.)|June 24, 2023
Lipid Nanoparticle-Mediated Delivery of miRNA Mimics to Myeloid CellsElaine Kang, Marcin Kortylewski
Contemporary Oncology (Poznan, Poland)|April 10, 2018
The revival of CpG oligonucleotide-based cancer immunotherapiesTomasz Adamus, Marcin Kortylewski
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 2, 2007
Stat3 as a potential target for cancer immunotherapyMarcin Kortylewski, Hua Yu
Current Opinion in Immunology|May 16, 2008
Role of Stat3 in suppressing anti-tumor immunityMarcin Kortylewski, Hua Yu
Therapeutic Delivery|March 6, 2014
Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?Marcin Kortylewski, Sergey Nechaev
Oncoimmunology|October 24, 2014
The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapyMarcin Kortylewski, Sumanta K Pal
Oncoimmunology|April 9, 2016
Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancerSumanta K Pal, Marcin Kortylewski
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
Blood|June 3, 2021
Revisiting TLR9 as a target for CLL therapyMarcin Kortylewski
Cancer Immunology, Immunotherapy : CII|February 20, 2017
Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunitiesMarcin Kortylewski, Dayson Moreira
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 3, 2014
How to train your dragon: targeted delivery of microRNA to cancer cells in vivoMarcin Kortylewski, Sergey Nechaev
Methods in Molecular Biology (Clifton, N.J.)|June 24, 2023
Lipid Nanoparticle-Mediated Delivery of miRNA Mimics to Myeloid CellsElaine Kang, Marcin Kortylewski
Contemporary Oncology (Poznan, Poland)|April 10, 2018
The revival of CpG oligonucleotide-based cancer immunotherapiesTomasz Adamus, Marcin Kortylewski
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 2, 2007
Stat3 as a potential target for cancer immunotherapyMarcin Kortylewski, Hua Yu
Current Opinion in Immunology|May 16, 2008
Role of Stat3 in suppressing anti-tumor immunityMarcin Kortylewski, Hua Yu
Therapeutic Delivery|March 6, 2014
Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?Marcin Kortylewski, Sergey Nechaev
Oncoimmunology|October 24, 2014
The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapyMarcin Kortylewski, Sumanta K Pal
Oncoimmunology|April 9, 2016
Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancerSumanta K Pal, Marcin Kortylewski
Pageof 11